UBI Pharma Balans Gezondheid
Financiële gezondheid criteriumcontroles 4/6
UBI Pharma has a total shareholder equity of NT$1.2B and total debt of NT$92.5M, which brings its debt-to-equity ratio to 7.9%. Its total assets and total liabilities are NT$1.8B and NT$666.8M respectively. UBI Pharma's EBIT is NT$5.5M making its interest coverage ratio 0.9. It has cash and short-term investments of NT$340.3M.
Belangrijke informatie
7.9%
Verhouding schuld/eigen vermogen
NT$92.46m
Schuld
| Rente dekkingsratio | 0.9x |
| Contant | NT$340.30m |
| Aandelen | NT$1.17b |
| Totaal verplichtingen | NT$666.84m |
| Totaal activa | NT$1.84b |
Recente financiële gezondheidsupdates
Geen updates
Recent updates
Analyse van de financiële positie
Kortlopende schulden: 6562's short term assets (NT$680.4M) exceed its short term liabilities (NT$218.7M).
Langlopende schulden: 6562's short term assets (NT$680.4M) exceed its long term liabilities (NT$448.1M).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: 6562 has more cash than its total debt.
Schuld verminderen: 6562's debt to equity ratio has reduced from 85.7% to 7.9% over the past 5 years.
Schuldendekking: 6562's debt is not well covered by operating cash flow (7.5%).
Rentedekking: 6562's interest payments on its debt are not well covered by EBIT (0.9x coverage).